CN102038698A - New application of morroniside - Google Patents
New application of morroniside Download PDFInfo
- Publication number
- CN102038698A CN102038698A CN2009100192852A CN200910019285A CN102038698A CN 102038698 A CN102038698 A CN 102038698A CN 2009100192852 A CN2009100192852 A CN 2009100192852A CN 200910019285 A CN200910019285 A CN 200910019285A CN 102038698 A CN102038698 A CN 102038698A
- Authority
- CN
- China
- Prior art keywords
- morroniside
- sepsis
- group
- ethanol
- endotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 title claims abstract description 88
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 8
- 206010040047 Sepsis Diseases 0.000 abstract description 25
- 239000002158 endotoxin Substances 0.000 abstract description 17
- 238000010253 intravenous injection Methods 0.000 abstract description 11
- 210000002966 serum Anatomy 0.000 abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102100037907 High mobility group protein B1 Human genes 0.000 abstract description 7
- 210000000066 myeloid cell Anatomy 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 230000001476 alcoholic effect Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000037487 Endotoxemia Diseases 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000011218 segmentation Effects 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000239222 Tachypleus Species 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000252983 Caecum Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000018368 Triggering Receptor Expressed on Myeloid Cells-1 Human genes 0.000 description 2
- 108010066451 Triggering Receptor Expressed on Myeloid Cells-1 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000000849 HMGB Proteins Human genes 0.000 description 1
- 108010001860 HMGB Proteins Proteins 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000918728 Monotes Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses new application of morroniside, which provides the application of the morroniside in the preparation of medicines for treating or preventing sepsis. The intravenous injection of the morroniside can reduce the levels of sepsis rat serum HMGB1 (High-mobility Group-Box 1protein), TNF (Tumor Necrosis Factor)-alpha, IL (Interleukin)-6, endotoxin and TREM (Triggering Receptor Expressed on Myeloid Cells)-1.
Description
Technical field
The present invention relates to a kind of new purposes of morroniside, be specifically related to morroniside in preparation treatment or prevent application in the pyemic medicine.
Background technology
Sepsis (sepsis), i.e. pyemia.It is a kind of clinical syndrome that causes by infection.Suppurative pathogen is invaded blood flow and a large amount of therein breedings, and spreads to whole body with blood flow, the new multiple suppurative focus that causes at histoorgan.Sepsis is often with following sign: body temperature is higher or lower than normally, and leukocytosis or minimizing, tachycardia, rapid breathing or per minute ventilation raise unusually, as occurring wherein two or two above symptoms clinically, gets final product the diagnosis of sepsis mass formed by blood stasis; As the organ failure of occurring together, promptly be called serious symptom pyemia (severe sepsis).There is 500,000 pyemia patients every year in the U.S., survival rate only 55%～65%.
Sepsis is a common complication after severe trauma, burn, shock, the major operation, also is one of important cause of death of surgery critical patient.Research at present generally believes that lipopolysaccharide (LPS) is one of the crucial medium of generation inflammatory reaction in the toxic shock generating process [StaffM, WeintraubA, Widmalm G, et al.Structure determination oftheo-antigenic polysacchanide from the enteroinvasive Escherichia coli 1036.Eur JBiochem, 1999,263 (3): 65].Inflammatory mediator IL-6, TNF-α, HMGB-1 also play pivotal role [Cohen J.The immunopathogenesis of sepsis.Nature 2002,420 (6917): 885-891 in sepsis; WangH, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J.HMG-1 as a late mediatorof endotoxin lethality in mice.Science 1999,285 (5425): 248-251; Andersson U, TraceyKJ.HMGB1 in sepsis.Scand J Infect Dis 2003,35 (9): 577-584.].Myeloid cell triggers and is subjected to
Body (TREM-1) is sensitive indicator [the Ching LL that sepsis takes place, Wen YH, Ch LW, Hsu TK, Yen TL.Triggering receptor expressed on myeloid cells-1 in pleural effusions:A marker ofinflammatory disease.Resp Med 2007; 101:903-9.; Knapp S, Gibot S, de Vos A, VersteegHH, Colonna M, van der Poll T.Cutting edge:expression patterns of surface and solubletriggering receptor expressed on myeloid cells-1 in human endotoxemia.J Immunol 2004; 173:7131-4.; Gibot S, Kolopp-Sarda MN, B é n é MC, Bollaert PE, Lozniewski A, Mory F, Levy B, Faure GC.A soluble form of the triggering receptor expressed on myeloidcells-1 modulates the inflammatory response in murine sepsis.J Exp Med 2004; 200:1419-26.; Bouchon A, Facchetti F, Weigand MA, Colonna M.TREM-1 amplifies inflammationand is a crucial mediator of septic shock.Nature 2001; 410:1103-7.].
Morroniside is to extract the water miscible iridoid obtain from the Chinese medicine Fructus Corni, bibliographical information Fructus Corni water extract have blood sugar lowering, immunosuppressant, antiinflammatory, shock, heart tonifying,, effects such as arrhythmia, resisting fatigue, defying age and memory reinforcing.But morroniside is in the preparation treatment or prevent pyemic pharmacological action not appear in the newspapers.The inventor discovers that by a large amount of morroniside can trigger receptor (TREM-1) by the inflammation-inhibiting factor and myeloid cell and express, thus in and the serum endotoxin aspect prevention or the treatment sepsis tangible effect is being arranged.Based on this, the inventor provides morroniside by the inflammation-inhibiting factor expression, thus in and the serum endotoxin suppress pyemic and develop so that prevention or treatment sepsis.
Summary of the invention
The invention provides morroniside in preparation treatment or prevent application in the pyemic medicine.
Medicine provided by the invention is when being used to prevent sepsis, and the using dosage scope is 25mg～1000mg during its injection, preferred 25～500mg.
The present invention also provides the pharmaceutical composition of being made up of morroniside and pharmaceutically acceptable carrier or adjuvant, and said composition can be prepared into injection, freeze-dried powder with the pharmacy conventional method.
Morroniside provided by the invention prepares by the following method: the Fructus Corni pulverizing medicinal materials, add 6～12 times of water, and soaked 2 hours, decoct 2～3 times, decocted 1～2 hour at every turn, filter, the united extraction filtrate, being evaporated to relative density is 1.05～1.2, adds ethanol, stir, to concentration of alcohol be 60%～90%, left standstill 1～12 hour, filter alcoholic solution, small amount of ethanol washing filtering residue discards filtering residue, filtrate is concentrated into no ethanol, and is standby.Select the macroporous resin of nonpolar～low pole for use, regulator solution pH value to 1～3, last sample, absorption, 3～9 times of column volumes of water elution, 10%～50% alcoholic solution eluting, segmentation receives, elution volume is 3～15 times of column volumes, and the morroniside enriching section concentrates, and is standby.With sample on nonpolar～semipolar macroporous resin, get morroniside solution, the low-temperature reduced-pressure drying.Crystallization.
The inventor has confirmed the application of morroniside in treatment or prevention sepsis by following test, but effect is not limited thereto.
The specific embodiment
The preparation of embodiment 1 morroniside
Morroniside medical material 50Kg adds water 500L, soaks 2 hours, heating decocts 3 times, each 2 hours, filters, the united extraction filtrate, concentrating under reduced pressure is to relative density 1.20 (40 ℃ of mensuration), add 95% ethanol, stir, to concentration of alcohol be 80%, left standstill 2 hours, and filtered alcoholic solution, small amount of ethanol washing filtering residue, discard filtering residue, filtrate is concentrated into does not have alcohol, and regulating pH value is 2, last sample adsorbs 3 times of column volumes of 10% alcoholic solution eluting to the AB-8 macroporous resin column, 3 times of column volumes of 30% alcoholic solution eluting, 3 times of column volumes of 40% alcoholic solution eluting, 3 times of column volumes of 50% alcoholic solution eluting, segmentation receives, after testing, the person is concentrated into no ethanol to be rich in the morroniside.Sample adsorbs to the HPD300 resin column on this concentrated solution, 3 times of column volumes of purification washing, and 10% liquid alcoholic solution is washed 3 times of column volumes, and segmentation receives, and detects, and the person concentrates no ethanol, low-temperature reduced-pressure drying to be rich in the morroniside.Weigh, make morroniside 150g, content 91%, recrystallization in the ethanol, content 98.3%.
The preparation of embodiment 2 morronisides
Monot's medical material 50Kg adds water 500L, soaks 2 hours, heating decocts 3 times, each 2 hours, filters, the united extraction filtrate, concentrating under reduced pressure is to relative density 1.15 (40 ℃ of mensuration), add 95% ethanol, stir, to determining alcohol be 80%, left standstill 6 hours, and filtered alcoholic solution, wash filtering residue with small amount of ethanol, discard filtering residue, filtrate is concentrated into no ethanol.It is 2 that concentrated solution is regulated PH, and last sample adsorbs 3 times of column volumes of 10% ethanol elution to the HZ-818 macroporous resin column, 3 times of column volumes of 20% ethanol elution, 3 times of column volumes of 30% ethanol elution, 3 times of column volumes of 40% ethanol elution, segmentation receives, and after testing, the person is concentrated into no ethanol to be rich in the morroniside.Sample is to the HPD300 post on this concentrated solution, and 3 column volumes are washed in absorption, and 10% ethanol is washed 3 times of column volumes, and segmentation receives, and detects, and the person concentrates no ethanol to be rich in the morroniside.The low-temperature reduced-pressure drying.Crystallization is weighed, and makes morroniside 140g, content 92%, recrystallization in the ethanol, content 98.7%.
The preparation of embodiment 3 morroniside injection
Prescription:
Method for making:
Measure morroniside 2.5g by prescription, sodium chloride 225g with water for injection 25000ml dissolving, stirs; Add active carbon 25g, stirred 20 minutes, solution is clear and bright through filtering with microporous membrane, be sub-packed in the 250ml infusion bottle, and sterilization, packing gets final product after the passed examination.
Other checks that item should meet Pharmacopoeia of People's Republic of China version injection in 2005 project demand.
The preparation of embodiment 4 morroniside freeze-dried powders
Prescription:
Method for making:
Get morroniside 125g, being dissolved in 10000ml contains in the aqueous solution for injection of 1.25% mannitol, add active carbon 10g, stirred 30 minutes, solution obtains pyrogen-free settled solution through filtering with microporous membrane, be sub-packed in the 10ml cillin bottle, 2ml/ props up, and presses the lyophilizing of freeze-dried powder technology, makes every freeze-dried powder that contains 25mg.
Test the influence of the sepsis rat that 1 morroniside causes cecal ligation and perforation
1.1 medicine and reagent
Morroniside is by preparation example 1 preparation
Tachypleus amebocyte lysate test kit (the biochemical Industrial Co., Ltd of Foochow, Fujian Province Xin Bei, lot number: 080430)
High-mobility group-box 1protein (HMGB1), TNF-α, IL-6ELISA test kit (Shanghai Xi Tang biotech company)
Myeloid cell triggers receptor (TREM-1) ELISA test kit (Shanghai Hu Feng bio tech ltd)
Laboratory animal: SPF level Sprague Dawley rat, male, body weight 150g-200g, Shandong Luye Pharmaceutical Co., Ltd. is real
Testing animal center provides, and the animal quality certification number is: SYXK (Shandong) 20030020.
1.2 experimental technique and result
1.2.1 the preparation of cecal ligation and perforation (CLP) rat
Dorsal position is got in operation rat fasting in early morning on the same day behind the etherization, 75% ethanol disinfection abdominal part along the otch of hunter's line stage casing work one long 1.5cm, is cut off skin and flesh layer, detects the abdominal cavity and separates caecum; No. 1 silk thread is apart from cecum 1cm place (ileocecal valve far-end) ligation, and No. 16 puncture needle runs through caecum 3 times (triangular in shape) at ligation place far-end, the about 3mm of pin hole spacing, and extrude a little content; Caecum Hui Na abdominal cavity, layer-by-layer suture is closed the abdominal cavity.
1.2.2 grouping administration
60 of CLP rats are divided into 6 groups at random, and promptly model group, morroniside intravenous injection 2.5mg/kg, 5mg/kg, 25mg/kg, 50mg/kg, 100mg/kg get 10 normal rats in addition and organize in contrast.1 hour each group of CLP operation gives relative medicine.Blood was got in the CLP operation in 20 hours, measured serum HMGB1, TNF-α, IL-6, endotoxin.Serum HMGB, TNF-α, IL-6 measure and use the ELISA test kit, and the serum endogenous toxin uses plain tachypleus amebocyte lysate kit measurement.
1.2.3 experimental result
Morroniside intravenous injection 2.5mg/kg, 5mg/kg, 25mg/kg, 50mg/kg, 100mg/kg group obviously reduce sepsis rat blood serum HMGB1, TNF-α, IL-6, endotoxin, TREM-1 level (p＜0.05 or p＜0.01).Morroniside intravenous injection 50mg/kg group reduces relatively there was no significant difference of sepsis rat blood serum HMGB1, TNF-α, IL-6, endotoxin, TREM-1 level and morroniside intravenous injection 100mg/kg group.
The influence (n=10) of the sepsis rat that the intravenous injection of table 1 morroniside causes cecal ligation and perforation
*, p＜0.05,
*, compare with model group p＜0.01
Test of the influence of 2 morronisides to the endotoxemia rat
2.1 material
Morroniside is by preparation example 1 preparation
Endotoxin: microorganism teaching and research room of Shanghai The 2nd Army Medical College, lot number: 070412
D-galactosamine (import packing, 5g/ bottle, Beijing chemical reagents corporation, lot number: 070412)
Tachypleus amebocyte lysate test kit (the biochemical Industrial Co., Ltd of Foochow, Fujian Province Xin Bei, lot number: 070430)
Laboratory animal: SPF level Sprague Dawley rat, male, body weight 150g-200g, Shandong Green Leaf Pharmaceutical Co., Ltd's Experimental Animal Center provides, and the animal quality certification number is: SYXK (Shandong) 20030020.
2.2 experimental technique and result
Rat is divided into NS group, dexamethasone 5mg/kg group, intravenous injection morroniside 100mg/kg group, 50mg/kg group, 25mg/kg group, 5mg/kg group, 2.5mg/kg group, 10 every group at random.Rat fasting 16h before the experiment can't help water.During experiment through tail vein injection D-galactosamine (300mg/kg), carry out modeling through intragastric infusion endotoxin (20mg/kg) immediately, respectively organize administration immediately, the NS group gives the NS with volume, each group is got blood respectively at 24h eye socket after the modeling, get 10 normal rats simultaneously and get blood, measure level of endotoxin in the blood plasma.Plasma endotoxin is measured with adopting the tachypleus amebocyte lysate chromogenic substrate method, and statistical procedures is carried out in the T check between group.
Table 2 result of the test shows that morroniside intravenous injection 2.5mg/kg, 5mg/kg, 25mg/kg, 50mg/kg, 100mg/kg group can significantly reduce level of endotoxin in the endotoxemia rat plasma and (compare with the NS group, P＜0.01), intravenous injection morroniside 10mg/kg can obviously reduce level of endotoxin in the endotoxemia rat plasma (comparing P＜0.05 or P＜0.01 with model group).Morroniside intravenous injection 50mg/kg group reduces sepsis rat blood serum level of endotoxin and morroniside intravenous injection 100mg/kg group compares there was no significant difference.
Table 2 morroniside is to level of endotoxin influence (n=10) in the endotoxemia rat plasma
Compare with the NS group,
*: p＜0.05;
*: p＜0.01.
Claims (1)
1. morroniside is in preparation treatment or prevent application in the pyemic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100192852A CN102038698A (en) | 2009-10-14 | 2009-10-14 | New application of morroniside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100192852A CN102038698A (en) | 2009-10-14 | 2009-10-14 | New application of morroniside |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102038698A true CN102038698A (en) | 2011-05-04 |
Family
ID=43905462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100192852A Pending CN102038698A (en) | 2009-10-14 | 2009-10-14 | New application of morroniside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038698A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110025626A (en) * | 2019-05-10 | 2019-07-19 | 厦门大学 | Application of the morroniside in preparation treatment chordapsus drug |
| US11186636B2 (en) | 2017-04-21 | 2021-11-30 | Amgen Inc. | Anti-human TREM2 antibodies and uses thereof |
-
2009
- 2009-10-14 CN CN2009100192852A patent/CN102038698A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11186636B2 (en) | 2017-04-21 | 2021-11-30 | Amgen Inc. | Anti-human TREM2 antibodies and uses thereof |
| CN110025626A (en) * | 2019-05-10 | 2019-07-19 | 厦门大学 | Application of the morroniside in preparation treatment chordapsus drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106937959B (en) | A kind of antitumor extra large Blatta seu periplaneta extract and its preparation technology and detection method and purposes | |
| CN101637474B (en) | New application of dipsacoside VI | |
| CN101161251A (en) | On-off total saponin as well as its extracting method and application | |
| CN113150049B (en) | Cyclocarya paliurus extract and application thereof in resisting gout and reducing uric acid | |
| CN102068535B (en) | Immature bitter orange or bitter orange total flavonoids extract prepared by ethanol reflux and extraction and application thereof | |
| CN104107187B (en) | The application in treatment diabetes medicament of a kind of Herba Apocyni veneti acidic polysaccharose | |
| CN105646611B (en) | A kind of dicaffeoyl spermidine derivative glycoside and use thereof | |
| CN102038698A (en) | New application of morroniside | |
| CN101028322B (en) | Application of Butterbur pilaris Extract in the Preparation of Drugs for Preventing and Treating Tumor Diseases | |
| CN105566269B (en) | Preparation, pharmacological action and the application for treating itch of coumarin derivative | |
| CN101293016A (en) | Application of Cistanche deserticola extract in preparation of medicament for treating Parkinson's disease | |
| CN100594913C (en) | Pharmaceutical composition for treating diabetes and its complications, its preparation method and application | |
| Wu et al. | Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress | |
| Wang et al. | Screening the hemostatic active fraction of Artemisia annua L. in-vitro | |
| Reddy et al. | Development and in vitro evaluation of glibenclamide Aloe barbadensis miller leaves mucilage controlled release matrix tablets | |
| CN102018747B (en) | Application of red stilbene and red stilbene polysaccharide in preparing medicament for improvement of learning memory and treatment of Alzheimer disease | |
| CN115894735A (en) | A kind of eagle tea acidic polysaccharide and its extraction and purification method and anticancer application | |
| CN103191238A (en) | Fructus aurantii immaturus or fructus aurantii total-flavonoid extract obtained through ethanol reflux extraction and application thereof | |
| CN107362237B (en) | A kind of tea kudzu extract with antifungal effect and its preparation method and use | |
| CN1788753B (en) | General glycoside extract from tree peony root bark and its preparation method and uses thereof | |
| CN106420850B (en) | Compositions extracted from gingko biloba leaves and its preparing the application in Shu Xuening injection | |
| CN114213480B (en) | Glycoside compound, pharmaceutical composition, preparation method and application | |
| Hossain et al. | Antidiabetic and glycogenesis effects of different fractions of methanolic extract of Momordica charantia (Linn.) in alloxan induced diabetic rats | |
| CN103845353A (en) | New use of astragaloside A | |
| CN103585469B (en) | A kind of gymnadenia conopsea medicinal composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EM01 | Change of recordation of patent licensing contract |
Change date: 20101223 Contract record no.: 2010320000507 Assignee after: Nanjing Luye Pharmaceutical Co., Ltd. Assignee before: Kanghai Pharmaceutical Co., Ltd., Nanjing |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Nanjing Luye Pharmaceutical Co., Ltd. Assignor: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. Contract record no.: 2010320000507 Denomination of invention: New application of morroniside License type: Exclusive License Open date: 20110504 Record date: 20100430 |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110504 |